(3 years, 1 month ago)
Commons ChamberThe research is being undertaken in a number of academic institutions, as far as I am aware. I am happy to dig out the detail of where specifically this is being researched—I do not have it to hand. It is worth reinforcing the point that the process for the rescheduling of compounds is that approval is given for a medicine by the MHRA, and advice is then taken from the ACMD as to the rescheduling, as we did with Epidyolex. As soon as those medicines are approved by the MHRA for use, I would be happy to consider rescheduling.